Orexin's role in the neurobiology of addiction
Treatments studied
Part of Mental health clinical trials.
This study looks at how a brain chemical called orexin affects addiction. Researchers will give a medication that blocks orexin to see if it helps reduce cravings or use. It might help people who smoke or vape regularly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 60 years old
- Be able to read and understand English for safety reasons
- For smokers/vapers: use nicotine at least 4 times per week for the past year and have a positive urine cotinine test
- No current drug or alcohol problems (except nicotine or marijuana)
- No history of major head injury, seizures, or brain disorders
- Not pregnant or breastfeeding
- No severe liver or heart issues
- No narcolepsy or sleep behavior problems
- No MRI contraindications (e.g., metal implants)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a beta-blocking medicine (propranolol) and nicotine patches change how strongly your brain responds to smoking cues. It may help researchers understand what drives cigarette cravings and how to reduce them.
This trial tests if a type of brain stimulation (TMS) can help people with nicotine dependence reduce cravings. It may be an option if you smoke or use e-cigarettes heavily and want to understand how your brain responds to treatment.
This study looks at how your brain reacts to smoking cues after using an oral nicotine pouch. You would need to try the pouch and avoid nicotine for 12 hours before each session.
This study looks at how young adults who vape react to oral nicotine pouches (like Zyn). It tests whether these products might be appealing or lead to misuse. You must be 21–25, an exclusive vaper, and never have used nicotine pouches before.
This study uses brain scans (MRI) to understand how craving affects decision-making in people with opioid use disorder. It compares their brain activity to healthy volunteers, which may lead to better treatments.
This study tests whether the medication suvorexant can reduce drug cravings in people with opioid use disorder. You will take either suvorexant or a placebo and have your cravings measured in a safe setting.
Hear when a new Nicotine Dependence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.